ZTS at a glance
Zoetis (ZTS, SEC CIK 1555280) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Zoetis (ZTS) reported revenue of $9.5 billion (up 2.3% from FY2024) and net income of $2.7 billion. Diluted EPS was $6.02.
- As of September 30, 2026, 50 institutional investment managers tracked by SignalX reported holding Zoetis (ZTS) shares worth $11.2 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $9.5B
- +2.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 50 funds
- $11.2B · −4 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- Cybersecurity risk with potential uninsured costs despite cybersecurity insurance coverage
- Dependency on third-party cloud infrastructure for critical information systems operations
- Board Audit Committee oversight of cybersecurity risk management and material incident disclosures
- Executive leadership includes IT veterans from Biogen and Eli Lilly enhancing cybersecurity governance
- Periodic third-party cybersecurity assessments every 18 months to evaluate controls per NIST Cybersecurity Framework
Management Discussion & Analysis
- Revenue $9,467M for 2025, up 2% YoY from $9,256M in 2024
- Net income $2,673M, increased 8% from $2,486M in 2024; adjusted net income $2,847M, up 6% YoY
- Operating segments: U.S. and International; best performing not specified, but U.S. and International product diversity provides stability
- Key risks: economic downturn, inflation impact on demand and collections; competition from generics causing 66% sales decline of Draxxin in U.S. since 2021
Business Overview
- No new products, services, or segments introduced or emphasized in 2026 filing text
- Strategic shifts or competitive positioning changes not disclosed in business section
- No quantitative business metrics or operational data provided for 2026
- Filing unusually focused on cross-references to proxy statements and governance documents, not on business operations or financial performance
AI summary of the ZTS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $2,391M, down $31M or 1% YoY, operational revenue down 2%
- Q3 cost-of-sales margin 70.8% vs 71.2% YoY, gross margin U.S. 82.2% vs 83.2%, International 68.9% vs 68.2%
- Best segment International: revenue $1,116M, up 4%; worst U.S.: revenue $1,246M, down 6%
- Nine-month operating cash flow $1,880M vs $2,056M; financing outflows $2,371M, including $1,659M share repurchases
- Headwinds: softer companion-animal demand, generic competition, tariffs, inflation, geopolitical uncertainty and foreign-exchange volatility
Risk Factors
- No material changes to risk factors disclosed in Zoetis’s 2025 Form 10-K
- Regulatory compliance risk: Existing 10-K risks remain incorporated by reference
- Operational risk: Existing MD&A operating-environment risks remain relevant to results
- Financial risk: Existing 10-K financial-condition risks remain unchanged
AI summary of the ZTS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced by Zoetis
- Full-year 2026 guidance issued, providing updated outlook for investors
Item EX-99.1: Item EX-99.1
- Q3 revenue $2.4B, down 1%; U.S. revenue $1.2B fell 6% as Companion Animal declined 8%
- International revenue $1.1B rose 4%, led by Livestock growth of 8% reported and 9% organically
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Iris Knobloch joins Zoetis’ Board effective December 1, 2026
- Board expands from twelve to thirteen directors, increasing governance capacity
Item EX-99.12: Item EX-99.12
- Iris Knobloch appointed Zoetis director effective December 1, 2026
- Board expands from 12 to 13 members, adding consumer strategy and digital transformation expertise
Item 7.01: Regulation FD Disclosure
- Zoetis announced Ms. Knobloch’s appointment on October 13, 2026
- Exhibit 99.1 contains the appointment press release and related details
Item EX-99.14: Item EX-99.14
- Quarterly dividend declared at $0.53 per share, signaling continued shareholder cash returns
- Record date October 30, 2026, determining eligible common shareholders
Item 7.01: Regulation FD Disclosure
- Quarterly dividend declared at $0.53 per share
- Payment scheduled for December 1, 2026
AI summaries of ZTS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ZTS
Don't miss the next ZTS filing
- Alerts as it files. A push when ZTS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ZTS, by share count.
- Ask anything. An AI agent that reads every ZTS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Stetter Mark | A | Oct 30, 2026 | 5.852 | $79.72 |
| Driscoll Rimma | A | Oct 9, 2026 | 277.772 | $26.17 |
| FULLER JULIE | A | Oct 9, 2026 | 367.788 | $26.17 |
| Lagano Roxanne | A | Oct 9, 2026 | 367.788 | $26.17 |
| PECK KRISTIN C | A | Oct 9, 2026 | 720.144 | $26.17 |
| Esch Kevin | A | Oct 9, 2026 | 360.073 | $26.17 |
| Ferran Astorga Jeannette | A | Oct 9, 2026 | 52.983 | $26.17 |
| Sarbaugh Keith | A | Oct 9, 2026 | 303.49 | $26.17 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $8.5B | $9.3B | $9.5B |
| Net Income | $2.3B | $2.5B | $2.7B |
| Net Margin | 27.4% | 26.9% | 28.2% |
| Balance Sheet | |||
| Total Assets | $14.3B | $14.2B | $15.5B |
| Equity | $5.0B | $4.8B | $3.3B |
| ROE | 46.9% | 52.1% | 80.2% |
| Per Share | |||
| EPS | - | $5.47 | $6.02 |
| Cash Flow | |||
| Operating CF | $2.4B | $3.0B | $2.9B |
| CapEx | $732.0M | $655.0M | $621.0M |
Source: XBRL data in Zoetis (ZTS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ZTS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 50 | $11.21B |
| Q2 2026 | 54 | $11.69B |
| Q1 2026 | 53 | $19.57B |
| Q4 2025 | 55 | $20.94B |
| Q3 2025 | 55 | $24.73B |
| Q2 2025 | 54 | $26.74B |
| Q1 2025 | 54 | $20.65B |
| Q4 2024 | 49 | $15.95B |
- JPMorgan Chase & Co+2.65M (+101%)
- Invesco Ltd+2.44M (+44%)
- Goldman Sachs Group+1.02M (+32%)
- Bridgewater Associates LP+342.0K (+255%)
- Renaissance Technologies LLC+257.2K (+18%)
- Millennium Management−1.40M (-77%)
- Citadel Advisors LLC−1.25M (-39%)
- BlackRock−901.9K (-2%)
- Morgan Stanley−850.2K (-10%)
- Raymond James Financial−835.4K (-48%)
- FMR LLC (Fidelity)−380.6K
- Loews Corporation−140.0K
- Northwest Bancshares, Inc.−46.8K
- Soros Fund Management−27.8K
- Equitable Holdings Inc−13.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 424 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ZTS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Oct 13, 2026 | - | - | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Oct 13, 2026 | - | - | - |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 14, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ZTS SEC filings: frequently asked questions
Which institutions hold ZTS stock?
As of September 30, 2026, the largest Zoetis (ZTS) holders among the 13F filers tracked by SignalX were BlackRock ($2.7 billion), Vanguard Capital Management LLC ($1.8 billion), Vanguard Portfolio Management LLC ($1.6 billion), State Street Corp ($1.4 billion), Morgan Stanley ($560.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ZTS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Zoetis (ZTS) reported revenue of $9.5 billion (up 2.3% from FY2024) and net income of $2.7 billion. Diluted EPS was $6.02. The figures come from the XBRL data in the 10-K.
What are the main risks in ZTS's latest 10-K?
In the 10-K filed February 12, 2026, Zoetis (ZTS) flagged: Cybersecurity risk with potential uninsured costs despite cybersecurity insurance coverage. Dependency on third-party cloud infrastructure for critical information systems operations. (AI summary of the Risk Factors section.)
What did ZTS report in its latest 8-K?
Zoetis (ZTS) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced by Zoetis.
What are the latest ZTS SEC filings?
Zoetis (ZTS) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 3, 2026.
What is ZTS's SEC CIK number?
Zoetis (ZTS)'s SEC Central Index Key (CIK) is 1555280. EDGAR lists every ZTS filing under that number.
Ask anything about ZTS
The research agent reads ZTS's filings, financials, insider trades and 13F holders, then answers with sources.